SFI
BTAI icon

Susquehanna Fundamental Investments’s BioXcel Therapeutics BTAI Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-630
Closed -$306K – 1464
2021
Q3 		$306K Buy
+630
New +$277K 0.01% 1403

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna Fundamental Investments's BTAI Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of BioXcel Therapeutics (BTAI) in Q4 2021, closing a stake of 630 shares — an estimated $306K sold.

Susquehanna Fundamental Investments first reported a position in BTAI in Q3 2021 and held it in 1 quarter. The position peaked at $306K in Q3 2021. 93 funds tracked by Wall St. Rank hold BTAI as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining BioXcel Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 630 BioXcel Therapeutics shares in Q4 2021, an estimated $306K.
  • Susquehanna Fundamental Investments first reported a position in BioXcel Therapeutics in Q3 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's BioXcel Therapeutics position peaked at $306K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.